HRP20110763T1 - Makrolidni konjugati s protuupalnom aktivnošću - Google Patents
Makrolidni konjugati s protuupalnom aktivnošću Download PDFInfo
- Publication number
- HRP20110763T1 HRP20110763T1 HR20110763T HRP20110763T HRP20110763T1 HR P20110763 T1 HRP20110763 T1 HR P20110763T1 HR 20110763 T HR20110763 T HR 20110763T HR P20110763 T HRP20110763 T HR P20110763T HR P20110763 T1 HRP20110763 T1 HR P20110763T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- solvate
- treatment
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 16
- 239000012453 solvate Substances 0.000 claims abstract 15
- 238000004519 manufacturing process Methods 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 5
- 230000004968 inflammatory condition Effects 0.000 claims 5
- 208000006673 asthma Diseases 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
Abstract
Spoj, naznačen time što ima strukturuili njegova farmaceutski prihvatljiva sol ili solvat. Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Spoj, naznačen time što ima strukturu
[image]
ili njegova farmaceutski prihvatljiva sol ili solvat.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima strukturu
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima strukturu
[image]
.
4. Farmaceutski pripravak naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, kao i farmaceutski prihvatljiv razrjeđivač ili podlogu.
5. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u medicinskoj terapiji.
6. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju astme.
7. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju kronične opstruktivne plućne bolesti.
8. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju upalne bolesti crijeva.
9. Spoj, ili njegova farmaceutski prihvatljiva sol ili solvat, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju psorijaze.
10. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s nepoželjnim upalnim imunosnim odgovorom, te svim bolestima i stanjima uzrokovanim ili povezanim s prekomjernim izlučivanjem TNF-α i IL-1.
11. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje upalnih stanja i imunosnih ili anafilaktičkih poremećaja povezanih s infiltracijom leukocita u upaljeno tkivo.
12. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se upalna stanja i imunosne poremećaje bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, kronična opstruktivna plućna bolest, upalna stanja crijeva, Crohnova bolest, bronhitis i cistična fibroza.
13. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedena upalna stanja i imunosne poremećaje bira iz skupine koju čine upalna stanja ili imunosni poremećaji pluća, zglobova, očiju, crijeva, kože i srca.
14. Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedena upalna stanja i imunosne poremećaje bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, bronhitis, cistična fibroza, reumatoidni artritis, reumatoidni spondilitis, osteoartritis, gihtični artritis, uveitis, konjunktivitis, upalna stanja crijeva, Crohnova bolest, ulcerozni kolitis, distalni proktitis, psorijaza, ekzem, dermatitis, oštećenje nakon koronarnog infarkta, kronična upala, endotoksinski šok, te poremećaji proliferacije glatkih mišića.
15. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
16. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje astme.
17. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kronične opstruktivne plućne bolesti.
18. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje upalne bolesti crijeva.
19. Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje psorijaze.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR20030324A HRP20030324A2 (en) | 2003-04-24 | 2003-04-24 | Compounds of antiinflammatory effect |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110763T1 true HRP20110763T1 (hr) | 2011-11-30 |
Family
ID=33307078
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030324A HRP20030324A2 (en) | 2003-04-24 | 2003-04-24 | Compounds of antiinflammatory effect |
HR20090551T HRP20090551T1 (hr) | 2003-04-24 | 2009-10-15 | Makrolidni konjugati s protuupalnom aktivnošću |
HR20110763T HRP20110763T1 (hr) | 2003-04-24 | 2011-10-19 | Makrolidni konjugati s protuupalnom aktivnošću |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030324A HRP20030324A2 (en) | 2003-04-24 | 2003-04-24 | Compounds of antiinflammatory effect |
HR20090551T HRP20090551T1 (hr) | 2003-04-24 | 2009-10-15 | Makrolidni konjugati s protuupalnom aktivnošću |
Country Status (28)
Country | Link |
---|---|
US (1) | US7579334B2 (hr) |
EP (2) | EP2070940B1 (hr) |
JP (1) | JP4613366B2 (hr) |
KR (1) | KR101107336B1 (hr) |
CN (1) | CN100393741C (hr) |
AR (1) | AR044083A1 (hr) |
AT (1) | ATE518876T1 (hr) |
AU (1) | AU2004232546B2 (hr) |
BR (1) | BRPI0410490A (hr) |
CA (1) | CA2523081C (hr) |
CL (1) | CL2004000872A1 (hr) |
CY (2) | CY1109491T1 (hr) |
DE (1) | DE602004022047D1 (hr) |
DK (2) | DK1633771T3 (hr) |
ES (2) | ES2330109T3 (hr) |
HK (2) | HK1086842A1 (hr) |
HR (3) | HRP20030324A2 (hr) |
IS (2) | IS2736B (hr) |
ME (1) | MEP34708A (hr) |
MX (1) | MXPA05011359A (hr) |
NO (2) | NO333909B1 (hr) |
PL (2) | PL2070940T3 (hr) |
PT (2) | PT1633771E (hr) |
RS (1) | RS52621B (hr) |
RU (1) | RU2355699C2 (hr) |
SI (2) | SI1633771T1 (hr) |
WO (1) | WO2004094449A1 (hr) |
ZA (1) | ZA200508388B (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
EP1723159B1 (en) | 2004-02-27 | 2019-06-12 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
BRPI0514254A (pt) * | 2004-08-12 | 2008-06-03 | Glaxosmithkline Zagreb | uso de conjugados célula-especìficos para o tratamento de doenças inflamatórias do trato gastrintestinal |
US20060183696A1 (en) * | 2004-08-12 | 2006-08-17 | Pliva-Istrazivacki Institut D.O.O. | Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract |
ES2337915T3 (es) | 2004-10-27 | 2010-04-30 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Conjugados con adtividad antiinflamatoria. |
TWI423819B (zh) * | 2005-12-22 | 2014-01-21 | Hydra Biosciences Inc | 用於調節trpa1功能之化合物 |
WO2007093840A2 (en) * | 2006-02-15 | 2007-08-23 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract |
EP2262483A2 (en) * | 2008-03-05 | 2010-12-22 | Panacea Biotec Limited | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof |
CN102838660B (zh) * | 2011-06-23 | 2016-11-02 | 上海市第一人民医院 | 一种抑制炎症免疫反应的小肽及其应用 |
US20140256696A1 (en) | 2013-03-08 | 2014-09-11 | Allergan, Inc. | Steroid conjugates |
WO2014138343A1 (en) * | 2013-03-08 | 2014-09-12 | Allergan, Inc. | Antibiotic conjugates with nonsteroidal anti-inflammatory drugs |
BR112015021836A2 (pt) | 2013-03-08 | 2017-07-18 | Allergan Inc | conjugados de antibióticos diretamente ligados com drogas esteroides |
JP2016510753A (ja) * | 2013-03-08 | 2016-04-11 | アラーガン、インコーポレイテッドAllergan,Incorporated | ステロイド薬と結合した抗生物質共役体 |
WO2016013030A2 (en) | 2014-07-23 | 2016-01-28 | Sphaera Pharma Pvt. Ltd. | Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0257956B2 (en) | 1986-08-19 | 2000-11-22 | Genentech, Inc. | Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion |
DE3860503D1 (de) * | 1987-09-03 | 1990-10-04 | Pliva Pharm & Chem Works | 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung. |
SE9100341D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroids |
SE9100342D0 (sv) | 1991-02-04 | 1991-02-04 | Astra Ab | Novel steroid esters |
GB9225923D0 (en) | 1992-12-11 | 1993-02-03 | Rhone Poulenc Rorer Ltd | New compositions of matter |
CA2149777C (en) | 1992-12-24 | 2004-05-25 | Michael John Ashton | New steroids |
KR970704455A (ko) | 1994-08-12 | 1997-09-06 | 우에하라 아끼라 | 인터류킨 5 생성 억제제(Interleukin 5 Production Inhibitor) |
WO1996004920A1 (fr) | 1994-08-12 | 1996-02-22 | Taisho Pharmaceutical Co., Ltd. | Inhibiteur de production de l'interleukine-5 |
DE19616573C2 (de) | 1996-04-25 | 1999-03-04 | Pari Gmbh | Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase |
JP3530004B2 (ja) | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
WO2000025776A1 (en) * | 1998-10-30 | 2000-05-11 | Nitromed, Inc. | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
IT1306205B1 (it) | 1999-01-15 | 2001-05-30 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
HRP20000310A2 (en) | 2000-05-17 | 2002-02-28 | Pliva Farmaceutska Ind Dioniko | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
FI110835B (fi) | 2000-07-11 | 2003-03-31 | Radiolinja Ab | Menetelmä palvelunumeropuhelun tarjoamiseksi matkaviestintilaajalle ennalta määrätyllä taksalla |
HRP20010018A2 (en) | 2001-01-09 | 2002-12-31 | Pliva D D | Novel anti-inflammatory compounds |
US20040186063A1 (en) * | 2002-02-15 | 2004-09-23 | Hans-Jurgen Gutke | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
US20050171342A1 (en) * | 2002-02-15 | 2005-08-04 | Michael Burnet | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
EP1483579A4 (en) * | 2002-02-15 | 2006-07-12 | Merckle Gmbh | CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THE PREPARATION AND USE OF CONJUGATES, FORMULATION AND PHARMACEUTICAL APPLICATIONS OBTAINED FROM SUCH CONJUGATES |
EP1551865B1 (en) * | 2002-07-08 | 2009-04-22 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Hybrid molecules of macrolides with steroidal/non-steroidal anti-inflammatory molecules |
PL374646A1 (en) | 2002-07-08 | 2005-10-31 | Pliva-Istrazivacki Institutt D.O.O. | Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
CA2489402A1 (en) * | 2002-07-08 | 2004-01-15 | Pliva-Istrazivacki Institut D.O.O. | New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
-
2003
- 2003-04-24 HR HR20030324A patent/HRP20030324A2/hr not_active Application Discontinuation
-
2004
- 2004-04-22 US US10/830,858 patent/US7579334B2/en not_active Expired - Fee Related
- 2004-04-23 PL PL09075145T patent/PL2070940T3/pl unknown
- 2004-04-23 AU AU2004232546A patent/AU2004232546B2/en not_active Ceased
- 2004-04-23 CN CNB2004800110487A patent/CN100393741C/zh not_active Expired - Fee Related
- 2004-04-23 CL CL200400872A patent/CL2004000872A1/es unknown
- 2004-04-23 DK DK04729157T patent/DK1633771T3/da active
- 2004-04-23 WO PCT/IB2004/001235 patent/WO2004094449A1/en active Application Filing
- 2004-04-23 PL PL04729157T patent/PL1633771T3/pl unknown
- 2004-04-23 MX MXPA05011359A patent/MXPA05011359A/es active IP Right Grant
- 2004-04-23 RS YU20050873A patent/RS52621B/en unknown
- 2004-04-23 RU RU2005131937/04A patent/RU2355699C2/ru not_active IP Right Cessation
- 2004-04-23 PT PT04729157T patent/PT1633771E/pt unknown
- 2004-04-23 CA CA2523081A patent/CA2523081C/en not_active Expired - Lifetime
- 2004-04-23 SI SI200431253T patent/SI1633771T1/sl unknown
- 2004-04-23 KR KR1020057020252A patent/KR101107336B1/ko not_active IP Right Cessation
- 2004-04-23 PT PT09075145T patent/PT2070940E/pt unknown
- 2004-04-23 ES ES04729157T patent/ES2330109T3/es not_active Expired - Lifetime
- 2004-04-23 SI SI200431768T patent/SI2070940T1/sl unknown
- 2004-04-23 AT AT09075145T patent/ATE518876T1/de active
- 2004-04-23 DK DK09075145.4T patent/DK2070940T3/da active
- 2004-04-23 AR ARP040101400A patent/AR044083A1/es unknown
- 2004-04-23 ME MEP-347/08A patent/MEP34708A/xx unknown
- 2004-04-23 BR BRPI0410490-0A patent/BRPI0410490A/pt not_active Application Discontinuation
- 2004-04-23 EP EP09075145A patent/EP2070940B1/en not_active Expired - Lifetime
- 2004-04-23 EP EP04729157A patent/EP1633771B1/en not_active Expired - Lifetime
- 2004-04-23 ES ES09075145T patent/ES2370371T3/es not_active Expired - Lifetime
- 2004-04-23 DE DE602004022047T patent/DE602004022047D1/de not_active Expired - Lifetime
- 2004-04-23 JP JP2006506511A patent/JP4613366B2/ja not_active Expired - Fee Related
-
2005
- 2005-10-17 ZA ZA200508388A patent/ZA200508388B/xx unknown
- 2005-11-22 IS IS8141A patent/IS2736B/is unknown
- 2005-11-23 NO NO20055535A patent/NO333909B1/no not_active IP Right Cessation
-
2006
- 2006-08-09 HK HK06108841.8A patent/HK1086842A1/xx not_active IP Right Cessation
-
2009
- 2009-07-24 HK HK09106861.4A patent/HK1129681A1/xx not_active IP Right Cessation
- 2009-10-14 CY CY20091101070T patent/CY1109491T1/el unknown
- 2009-10-15 HR HR20090551T patent/HRP20090551T1/hr unknown
-
2010
- 2010-12-29 IS IS8941A patent/IS8941A/is unknown
-
2011
- 2011-10-19 HR HR20110763T patent/HRP20110763T1/hr unknown
- 2011-10-25 CY CY20111101008T patent/CY1111978T1/el unknown
-
2013
- 2013-06-28 NO NO20130898A patent/NO335552B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110763T1 (hr) | Makrolidni konjugati s protuupalnom aktivnošću | |
JP2018513107A5 (hr) | ||
JP2009531292A5 (hr) | ||
JP2009510044A5 (hr) | ||
EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
JP2005523338A5 (hr) | ||
RU2008137086A (ru) | Борсодержащие малые молекулы в качестве противовоспалительных средств | |
JP2005515966A5 (hr) | ||
HRP20100359T1 (hr) | Specifični glukokortikoidni spoj s protuupalnom aktivnošću | |
RU2010113569A (ru) | Производное бензохинона е3330 в комбинации с химиотерапевтическими агентами для лечения рака и ангиогенеза | |
JP2005510535A5 (hr) | ||
CY1107498T1 (el) | Φαρμακευτικη συνθεση πepιλαμβανουσα ρεσβepατρολη για την αγωγη φλεγμονωδων αναπνευστικων διαταραχων | |
JP2008526950A5 (hr) | ||
JP2017222722A5 (hr) | ||
RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
JP2018009002A5 (hr) | ||
JP2017080507A5 (hr) | ||
CN114450275A (zh) | 杂芳基氨基吡啶醇衍生物以及包含其为活性成分的用于预防或治疗自身免疫性疾病的药物组合物 | |
JP2013544244A5 (hr) | ||
JP2015508765A5 (hr) | ||
HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
IL250271B2 (en) | A mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies | |
RU2013127793A (ru) | Противовоспалительные композиции | |
JP2015514797A5 (hr) | ||
JP2011157375A5 (hr) |